Literature DB >> 8395127

Characteristics and location of cross-reactive and serotype-specific neutralization sites on VP7 of human G type 9 rotaviruses.

C Kirkwood1, P J Masendycz, B S Coulson.   

Abstract

The neutralization antigens of human rotavirus VP7 were studied by producing eight neutralizing monoclonal antibodies to G type 9 rotaviruses F45 and WI61 and selecting antigenic variants resistant to neutralization by these monoclonal antibodies. Neutralization resistance patterns and sequence analysis of the antigenic variants indicated the presence of overlapping serotype-specific and serotype cross-reactive epitopes in antigenic region A, and one distinct type-specific epitope. Cross-reactive monoclonal antibodies were more tolerant of amino acid sequence change than type-specific monoclonal antibodies. The existence of a new antigenic region, F, including amino acids 235 to 242 was confirmed. This region contained a cross-reactive epitope not detectable in the presence of glycosylation at amino acid 238. This glycosylation also affected neutralization by a cross-reactive monoclonal antibody directed to antigenic region C. Antigenic regions A, B, C, and F all contain epitopes shared between G types, of which at least two (C and F) are affected by glycosylation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395127     DOI: 10.1006/viro.1993.1456

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Emergence of serotype G9 human rotaviruses in Australia.

Authors:  E A Palombo; P J Masendycz; H C Bugg; N Bogdanovic-Sakran; G L Barnes; R F Bishop
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Molecular characterization of porcine rotaviruses from the southern region of Brazil: characterization of an atypical genotype G[9] strain.

Authors:  M L Rácz; S S Kroeff; V Munford; T A Caruzo; E L Durigon; Y Hayashi; V Gouvea; E A Palombo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Amino acid substitution within the VP7 protein of G2 rotavirus strains associated with failure to serotype.

Authors:  M I Gómara; D Cubitt; U Desselberger; J Gray
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Evidence of high-frequency genomic reassortment of group A rotavirus strains in Bangladesh: emergence of type G9 in 1995.

Authors:  L E Unicomb; G Podder; J R Gentsch; P A Woods; K Z Hasan; A S Faruque; M J Albert; R I Glass
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

5.  Eight-year survey of human rotavirus strains demonstrates circulation of unusual G and P types in Hungary.

Authors:  Krisztián Bányai; Jon R Gentsch; Roger I Glass; Mária Uj; Ilona Mihály; György Szücs
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

6.  Characterization of serotype G9 rotavirus strains isolated in the United States and India from 1993 to 2001.

Authors:  A R Laird; J R Gentsch; T Nakagomi; O Nakagomi; R I Glass
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

7.  Genetic and antigenic characterization of rotavirus serotype G9 strains isolated in Australia between 1997 and 2001.

Authors:  Carl Kirkwood; Nada Bogdanovic-Sakran; Enzo Palombo; Paul Masendycz; Helen Bugg; Graeme Barnes; Ruth Bishop
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

8.  Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs.

Authors:  Bingxin Zhao; Xiaoxia Pan; Yumei Teng; Wenyue Xia; Jing Wang; Yuling Wen; Yuanding Chen
Journal:  Virol Sin       Date:  2015-10-10       Impact factor: 4.327

9.  Epidemiology of symptomatic human rotaviruses in Bangalore and Mysore, India, from 1988 to 1994 as determined by electropherotype, subgroup and serotype analysis.

Authors:  S Aijaz; K Gowda; H V Jagannath; R R Reddy; P P Maiya; R L Ward; H B Greenberg; M Raju; A Babu; C D Rao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

10.  Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites.

Authors:  C D Kirkwood; R F Bishop; B S Coulson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.